Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia
The purpose of this study is to determine whether bendamustine is effective in the treatment of initial treatment of Chronic Lymphocytic Leukemia (CLL).
Chronic Lymphocytic Leukemia|Leukemia|Neoplasms
DRUG: Bendamustine Hydrochloride Injection|DRUG: Chlorambucil
Overall response rate (ORR), 24 months
Progress free survival(PFS), 24 months|Duration of Response (DR), 24 months|Overall Survival(OS), 24 months
The purpose of this study is to determine whether bendamustine is effective in the treatment of initial treatment of Chronic Lymphocytic Leukemia (CLL).